we are often asked: "How can a peel be powerful without the peeling?" The answer lies in the revolutionary chemistry of Biphasic TCA Technology, pioneered by BioRePeelCl₃Trichloroacetic acid (TCA) has long been used in dermatology for skin resurfacing. Traditionally, TCA peels were effective but often associated with downtime, frosting, inflammation, and risk of post-inflammatory hyperpigmentation, especially in darker skin types. Recent advancements in peel technology have transformed how TCA is delivered to the skin. One of the most important innovations is Biphasic TCA, a technology best represented by BioRePeelCl_3.

The Biphasic Mechanism: Lipophilic vs. Hydrophilic

Traditional Trichloroacetic Acid (TCA) peels are monophasic, meaning they often cause significant surface trauma (frosting and heavy shedding) to reach the deeper layers. BioRePeelCl₃ utilizes a patented biphasic technology that separates the formula into two distinct layers:

1. The Lipophilic Phase (Blue): This layer prevents the oxidation of the TCA and creates a "shield" on the skin surface. It reduces transepidermal water loss and helps the active ingredients bypass the epidermis without causing excessive surface irritation.

2. The Hydrophilic Phase (Yellow): This is the "powerhouse" layer. It contains 35% or 50% TCA, alongside alpha, beta, and polyhydroxy acids, amino acids, and vitamins. Because of the lipophilic "delivery vehicle," these acids are funneled directly into the dermis.

   
   

Beyond Resurfacing: Bio-Stimulation and Revitalization

 BioRePeelCl₃ is more than a peel; it is a Bio-Stimulator.

• Bio-Stimulation: It activates fibroblasts to increase the production of collagen and elastin.

• Revitalization: It enhances cellular turnover and stimulates biosynthetic processes within the skin matrix.

  
  

Why BioRePeel is Optimal for Indian Skin

Indian skin (Fitzpatrick types III-VI) is prone to Post-Inflammatory Hyperpigmentation (PIH) when exposed to high-heat lasers or aggressive monophasic peels. BioRePeel’s biphasic nature ensures that the "inflammatory signal" is controlled. By bypassing the surface trauma, we achieve deep dermal remodeling without the risk of secondary pigmentation associated with traditional high-concentration TCA.

Clinical Conclusion: BioRePeelCl₃ represents the future of medical aesthetics—maximum dermal activity with minimal social downtime.